US 12,138,347 B2
Nanoparticles and nanonetworks formed therefrom
Eva Harth, Houston, TX (US)
Assigned to University of Houston System, Houston, TX (US)
Appl. No. 17/291,079
Filed by University of Houston System, Houston, TX (US)
PCT Filed Nov. 5, 2019, PCT No. PCT/US2019/059763
§ 371(c)(1), (2) Date May 4, 2021,
PCT Pub. No. WO2020/097009, PCT Pub. Date May 14, 2020.
Claims priority of provisional application 62/755,611, filed on Nov. 5, 2018.
Prior Publication US 2021/0401750 A1, Dec. 30, 2021
Int. Cl. A61K 9/16 (2006.01); A61K 31/337 (2006.01); A61K 31/365 (2006.01); A61K 31/366 (2006.01); A61K 31/40 (2006.01); A61K 31/4745 (2006.01); A61K 31/519 (2006.01); A61K 31/58 (2006.01); A61K 31/704 (2006.01)
CPC A61K 9/1647 (2013.01) [A61K 31/337 (2013.01); A61K 31/365 (2013.01); A61K 31/366 (2013.01); A61K 31/40 (2013.01); A61K 31/4745 (2013.01); A61K 31/519 (2013.01); A61K 31/58 (2013.01); A61K 31/704 (2013.01)] 3 Claims
OG exemplary drawing
 
1. A therapeutic composition comprising:
a modified polyester having functional groups within the polyester backbone comprising

OG Complex Work Unit Chemistry
poly(Di(9-decenyl)Succinate-co-Di(4-pentenyl)Itaconate;
a secondary diamine crosslinking agent; and
a bioactive agent comprising Brefeldin A,
wherein the crosslinking agent reacts with the functional groups within the polyester backbone to form bonds between multiple polyester backbones, thereby forming a nanoparticle.